M

Moderna

Develops mRNA-based medicines for health

Process Engineering Co-op - CQV & Manufacturing Engineering

Winter 2027, Spring 2027Updated on 10/23/2026
$20 - $60+ Annual discretionary bonus + Incentive compensation + Equity award
Internship
Bachelor's, Master's
Norwood, MA, USA
In Person100% onsite at Norwood; work also supports Marlborough and Norwood sites based on project needs.
Biology & BiotechBioprocess & Biomanufacturing
No H1B Sponsorship

About the job

Requirements
  • Currently enrolled in a Bachelor's or Master's program in Chemical Engineering, Mechanical Engineering, Biomedical Engineering, Bioengineering, or another related Life Sciences Engineering discipline.
  • Have an interest in process engineering, manufacturing engineering, commissioning, qualification, validation, Good Manufacturing Practice (GMP) manufacturing, quality systems, equipment reliability, or regulated biopharmaceutical operations.
  • Have strong attention to detail, fundamental technical and problem-solving skills, and willingness to learn engineering and validation documentation practices.
  • Already hold U.S. work authorization and be able to maintain that status without future sponsorship.
  • Be willing and able to complete cleanroom gowning training and occasionally enter and observe manufacturing operations in a classified cleanroom environment.
Responsibilities
  • Support Process Engineering, Commissioning, Qualification and Validation (CQV), and Manufacturing Engineering team members with day-to-day activities for Good Manufacturing Practice (GMP) facilities, utilities, equipment, and systems across the Marlborough and Norwood sites, including incubators, centrifuges, ultrafiltration, chromatography, tangential flow filtration, robotic filling lines, visual inspection machines, automated label and pack lines, buffer preparation vessels, and utility support systems.
  • Assist with commissioning, qualification, and validation activities, including preparing, executing, reviewing, and organizing protocols, reports, traceability documents, field data, and supporting records.
  • Assist with troubleshooting process equipment, gathering information for root cause investigations, and supporting corrective and preventative actions, change controls, and preventative maintenance improvements.
  • Participate in engineering projects across the equipment lifecycle, including user requirements, design review, procurement, installation, start-up, commissioning, qualification, validation, and operational handover.
  • Support equipment and system qualification for manufacturing equipment, controlled temperature units, analytical instruments, process utilities, and supporting systems.
  • Review engineering and turnover documentation, including specifications, component lists, operating manuals, drawings, Engineering Turnover Packages, and qualification records, for completeness and compliance.
  • Partner with Quality, Manufacturing, Facilities, Metrology, Digital Automation, Manufacturing Science and Technology (MS&T), Environmental Health and Safety, and engineering groups across Marlborough and Norwood to support project and operational needs.
  • Participate in continuous improvement efforts by identifying documentation gaps, process inefficiencies, equipment reliability opportunities, and ways to strengthen engineering and validation execution.
  • Follow applicable Good Practice (GxP) regulations, standard operating procedures (SOPs), guidelines, safety requirements, and company policies; complete cleanroom gowning training and enter classified manufacturing areas as needed.
  • Communicate progress and issues clearly, complete assigned tasks on schedule, and prepare or contribute to technical documentation and project updates.
Desired Qualifications
  • Demonstrated ability to work independently and collaboratively in cross-functional teams.
  • Effective written and verbal communication skills, including the ability to ask questions, share updates, and document technical work clearly.
  • Basic proficiency with Microsoft Office tools; experience with technical writing, data organization, laboratory, engineering, or manufacturing environments is a plus.
  • Professional curiosity, accountability, and a desire to contribute to a fast-paced environment while supporting quality, safety, and compliance expectations.

About the company

Moderna develops medicines built on messenger RNA (mRNA). Its products use mRNA delivered into cells to instruct them to produce specific proteins that can prevent or treat disease, with vaccines being a primary example. In practice, a dose delivers engineered mRNA into the body, cells translate it into a target protein, and the immune system responds or the protein modulates biology to combat disease. Moderna differentiates itself through its focus on building a whole mRNA medicines platform and in-house capabilities for designing, manufacturing, and scaling mRNA therapies, including rapid development and large-scale production. Its goal is to create a new category of medicines based on mRNA that can improve how diseases are discovered, developed, and treated, ultimately improving patient outcomes.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Cambridge, Massachusetts

Founded

2010

Get referred to Moderna

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • September 2026 convertible notes raised $3 billion for oncology growth and debt flexibility.
  • April 21, 2026 European Commission approval made mCombriax the first authorized flu-COVID combo vaccine.
  • Second-quarter 2026 guidance targets up to 10% revenue growth and year-end cash of $4.7 billion.

What critics are saying

  • September 28, 2026, Delaware kept Bayer's mRNA patent case alive against Moderna.
  • July 15, 2026, Sanofi sued Moderna over COVID vaccine patents in New Jersey.
  • If intismeran fails beyond melanoma, Moderna remains a shrinking vaccine company.

What makes Moderna unique

  • Moderna's mRNA platform spans vaccines, oncology, and rare disease, unlike one-product peers.
  • September 30, 2026, Moderna added a COO to scale intismeran autogene manufacturing.
  • Bancel says Moderna owns mutation-selection software for personalized vaccines and synthetic, cell-free production.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • Health Savings Account/Flexible Spending Account
  • Unlimited Paid Time Off
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Sabbatical Leave
  • Hybrid Work Options

Growth & Insights and Company News

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Oct 23rd, 2026
Moderna sees $114.9M in net ETF buying as CGGO adds $121.1M stake

ETFs bought $114.9 million of Moderna stock on Wednesday, October 21, ending a one-day net selling streak. Twenty ETFs were buyers and 10 were sellers. CGGO led with 492,604 shares worth $121.1 million, a 1.06% portfolio weight. IBB added $2.0 million and QQQM $1.0 million. The flows followed a $7.5 million net outflow on October 20 and a $26.1 million net inflow on October 19. Over the last five reported days, ETFs were net buyers on three and net sellers on two. Moderna has a market cap of $80.9 billion. Its trailing 12-month revenue was $2.23 billion, down 27.3% over one year, and the shares have returned 587.11% so far this year.

Yahoo Finance
Oct 22nd, 2026
Moderna sinks 18% after leak of melanoma vaccine data showing 42% lower recurrence risk

Moderna shares fell 18% after detailed Phase 3 results for its personalised melanoma vaccine, developed with Merck, appeared online two days before their scheduled presentation. The data surfaced on medical news site Oncology Central and was taken down shortly afterwards. Trading in Moderna was halted for volatility. The leaked data still looks positive. Adding the vaccine, intismeran autogene, to Merck's Keytruda cut the risk of recurrence or death by 42% versus Keytruda alone. After two years, 82.2% of patients on the combination were alive and cancer-free, against 70% on Keytruda alone. The trial enrolled 1,137 patients. The stock had risen more than eightfold this year, and traded at about 52x forward sales before the drop. The 42% figure also trails the 49% from the smaller Phase 2b trial. Full results are due at the ESMO Congress on Saturday.

Yahoo Finance
Oct 21st, 2026
Moderna soars 600% to $90B market cap, but valuation leaves no margin for error

Moderna (NASDAQ: MRNA) has soared over 600% this year, making it the best performer among large-cap healthcare stocks. Eli Lilly gained 16% and Johnson & Johnson 22%. The rally followed US approval of mFLUSIVA, an influenza vaccine for people aged 50 and older. Moderna also said its personalised cancer vaccine, intismeran autogene, significantly improved recurrence-free survival in certain melanoma patients when combined with Merck's Keytruda. It is the first personalised vaccine to produce positive Phase 3 results. Moderna's market cap now stands at $90 billion. The average analyst price target of $123.61 implies a downside of about 45%. In the first six months of 2026, revenue rose 113.6% to $534 million, but net loss widened to $2.1 billion from $1.8 billion.

Yahoo Finance
Oct 21st, 2026
ServiceNow and Kinder Morgan are large-cap picks to watch; Moderna's $96.65B value underwhelms

StockStory, a stock research service, named two large-cap stocks to watch and one to avoid. It advises steering clear of Moderna, which has a market cap of $96.65 billion. Sales fell 20.5% annually over five years, and earnings per share dropped 24.5% annually. Its free cash flow margin fell 95.9 percentage points. The stock trades at $241.71, or 44.1x forward price-to-sales. ServiceNow ($154.6 billion market cap) grew annual recurring revenue 22.3% over the last year and has a free cash flow margin of 33.4%. It trades at $148.56 per share. Kinder Morgan ($74.75 billion market cap) reported $17.96 billion in revenue. Its shares trade at $33.64, or 22.5x forward earnings.

Yahoo Finance
Oct 19th, 2026
Moderna, Chemed and 10x Genomics: three healthcare stocks to avoid despite a 25.2% sector rally

Healthcare stocks have gained 25.2% over the past six months, beating the S&P 500 by 16.3 percentage points. Even so, StockStory warns that heavy regulation can hurt earnings, and names three stocks to avoid. Moderna, valued at $87.04 billion, has seen sales fall 20.5% a year over five years. Earnings per share dropped 24.5% annually, and the stock trades at 46x forward price-to-sales. Chemed, worth $6.67 billion, grew revenue 4.1% a year over five years, slower than its peers. Its adjusted operating margin fell 3.9 percentage points, and it trades at 20x forward earnings. 10x Genomics, valued at $9.10 billion, saw revenue decline 1.2% annually over two years to $616.9 million. Its returns on capital are negative.